Luiz Vicente Rizzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Luiz Vicente Rizzo has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
- Otavio Berwanger
Imperial College London, London, United Kingdom
6 shared publications - Alexandre Rodrigues Marra
Hospital Israelita Albert Einstein
4 shared publications - Elice Carneiro Batista
Hospital Israelita Albert Einstein, São Paulo, Brazil
4 shared publications - Frederico Monfardini
Hospital Israelita Albert Einstein, São Paulo, Brazil
4 shared publications - Henrique Andrade Rodrigues Fonseca
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
4 shared publications Camila Santos Nascimento de Albuquerque
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (5) , e70196
Mpox Airborne Transmission: A Systematic Review
Since May 2022, mpox has been reported across multiple nonendemic regions, with concurrent outbreaks in diverse geographic settings, raising concerns about broader international spread. However, evidence regarding the risk of airborne transmission remains limited. We conducted a systematic review to evaluate the risk of airborne transmission and the presence of viable viruses in air samples. PubMed, Web of Science, and the Cochrane Library were searched for studies published in English, including environmental studies, case reports, cross‐sectional studies, and cohort studies. Data extraction included study characteristics (authors, year, design, and setting), sample size, diagnostic methods, participant characteristics, follow‐up, type of respiratory particles assessed (droplets and/or aerosols), and key findings. Of 286 records identified, four studies met the inclusion criteria. All were environmental studies published between 2022 and 2023. MPXV DNA was detected in surface and air samples, with cycle threshold (Ct) values ranging from < 30 to < 45. However, none of the studies demonstrated consistent viral viability in aerosols or droplets sufficient to support airborne transmission. Overall, the available evidence is limited and does not support a clear risk of airborne infection. Further well‐designed studies in human settings are needed to clarify the potential for mpox transmission through respiratory routes. Systematic Review Registration: PROSPERO: CRD42023391123.
- 10 August 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (5) , e70196
Open AccessMpox Airborne Transmission: A Systematic Review
Since May 2022, mpox has been reported across multiple nonendemic regions, with concurrent outbreaks in diverse geographic settings, raising concerns about broader international spread. However, evidence regarding the risk of airborne transmission remains limited. We conducted a systematic review to evaluate the risk of airborne transmission and the presence of viable viruses in air samples. PubMed, Web of Science, and the Cochrane Library were searched for studies published in English, including environmental studies, case reports, cross‐sectional studies, and cohort studies. Data extraction included study characteristics (authors, year, design, and setting), sample size, diagnostic methods, participant characteristics, follow‐up, type of respiratory particles assessed (droplets and/or aerosols), and key findings. Of 286 records identified, four studies met the inclusion criteria. All were environmental studies published between 2022 and 2023. MPXV DNA was detected in surface and air samples, with cycle threshold (Ct) values ranging from < 30 to < 45. However, none of the studies demonstrated consistent viral viability in aerosols or droplets sufficient to support airborne transmission. Overall, the available evidence is limited and does not support a clear risk of airborne infection. Further well‐designed studies in human settings are needed to clarify the potential for mpox transmission through respiratory routes. Systematic Review Registration: PROSPERO: CRD42023391123.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500526
Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study
The treatment landscape of hepatocellular carcinoma (HCC) has evolved substantially; however, limited access to novel therapies and regional epidemiologic differences lead to heterogeneous real-world treatment patterns worldwide. The purpose of this study was to describe the epidemiology, treatment patterns, and outcomes of patients diagnosed with HCC in Brazil between 2017 and 2022. This was a national, multicenter, retrospective, real-world observational study including patients with confirmed HCC and first diagnosis between 2017 and 2022. Data were collected from 10 centers across four geographic regions in Brazil. Of 318 patients screened, 303 were included: 107 with early-stage disease Barcelona Clinic Liver Cancer (BCLC 0-B) and 196 with advanced-stage disease (BCLC C-D). The median age was 71 years (64-77); 77.6% were men, 48.5% self-identified as Black or mixed race, and 62% were treated in public institutions. Main etiologies were hepatitis C virus (35%), alcohol-related liver disease (27.4%), hepatitis B virus (7.6%), and metabolic dysfunction-associated steatotic liver disease (MASLD; 10.9%). Among early-stage patients, 57% was classified as Child-Pugh A and 85% received local therapy (26.7% surgery or ablation; 58.8% transarterial chemoembolization [TACE]/Drug-Eluting Bead-TACE). The median progression-free survival was 10.4 months (95% CI, 8.7 to 15.7), and the median overall survival (OS) was 19.6 months (95% CI, 15.9 to 29.0). In advanced disease, 41% was classified as Child-Pugh A, portal vein thrombosis was present in 39.8%, and extrahepatic disease was present in 42.9%. Systemic therapy was administered to 48.5% of patients. The median OS was 8 months with systemic therapy versus 3 months without treatment. In this Brazilian real-world cohort, hepatitis C and alcohol were the predominant etiologies, whereas MASLD accounted for 10% of cases. Although most localized cases received locoregional therapy with outcomes consistent with the literature, access to modern systemic treatments for advanced disease remained limited.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2500526
Real-World Epidemiology, Treatment Patterns, and Outcomes of Hepatocellular Carcinoma in Brazil: A Multicenter Retrospective Study
The treatment landscape of hepatocellular carcinoma (HCC) has evolved substantially; however, limited access to novel therapies and regional epidemiologic differences lead to heterogeneous real-world treatment patterns worldwide. The purpose of this study was to describe the epidemiology, treatment patterns, and outcomes of patients diagnosed with HCC in Brazil between 2017 and 2022. This was a national, multicenter, retrospective, real-world observational study including patients with confirmed HCC and first diagnosis between 2017 and 2022. Data were collected from 10 centers across four geographic regions in Brazil. Of 318 patients screened, 303 were included: 107 with early-stage disease Barcelona Clinic Liver Cancer (BCLC 0-B) and 196 with advanced-stage disease (BCLC C-D). The median age was 71 years (64-77); 77.6% were men, 48.5% self-identified as Black or mixed race, and 62% were treated in public institutions. Main etiologies were hepatitis C virus (35%), alcohol-related liver disease (27.4%), hepatitis B virus (7.6%), and metabolic dysfunction-associated steatotic liver disease (MASLD; 10.9%). Among early-stage patients, 57% was classified as Child-Pugh A and 85% received local therapy (26.7% surgery or ablation; 58.8% transarterial chemoembolization [TACE]/Drug-Eluting Bead-TACE). The median progression-free survival was 10.4 months (95% CI, 8.7 to 15.7), and the median overall survival (OS) was 19.6 months (95% CI, 15.9 to 29.0). In advanced disease, 41% was classified as Child-Pugh A, portal vein thrombosis was present in 39.8%, and extrahepatic disease was present in 42.9%. Systemic therapy was administered to 48.5% of patients. The median OS was 8 months with systemic therapy versus 3 months without treatment. In this Brazilian real-world cohort, hepatitis C and alcohol were the predominant etiologies, whereas MASLD accounted for 10% of cases. Although most localized cases received locoregional therapy with outcomes consistent with the literature, access to modern systemic treatments for advanced disease remained limited.
- Open Access
- 8 May 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (2) , 172-188
Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study
Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross‐sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020–2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease‐modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.
- 8 May 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (2) , 172-188
Open AccessClinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross‐Sectional Observational Study
Spinal muscular atrophy (SMA), linked to chromosome 5q, is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. It is classified into subtypes based on age at onset and the highest motor milestone achieved. This cross‐sectional observational study aimed to describe the clinical profile of patients with types 2 and 3 SMA followed within the Brazilian Public Health System (SUS). Clinical data from patients with types 2 and 3 SMA followed at nine national reference centers (2020–2021) were analyzed. A total of 155 patients were included: 76 with type 2 and 79 with type 3 SMA. Disease duration was longer in type 3 patients. Time from symptom onset to genetic confirmation was also longer in this group. Functional impairment was observed in both subtypes. Type 2 patients had lower HFMSE scores overall, though higher scores were seen among those on disease‐modifying therapies. In type 3, earlier symptom onset and longer disease duration were associated with worse motor outcomes. HFMSE scores varied with treatment use and disease duration. Findings reveal the clinical heterogeneity of SMA and emphasize the impact of diagnostic delays and disease duration on function. Early diagnosis and ongoing multidisciplinary care are crucial.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500324
Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study
PURPOSE: Disparities in health care access and resource availability in middle-income countries often lead to suboptimal management of localized bladder urothelial carcinoma (UC). However, real-world data describing treatment patterns and outcomes in these settings remain limited. METHODS: This multicenter, retrospective, real-world study included patients with high-risk non–muscle-invasive (HR-NMIBC) and localized muscle-invasive bladder cancer (MIBC) diagnosed between 2017 and 2022 across nine cancer centers in a middle-income setting. Treatment data and clinical outcomes were collected from medical records and analyzed using descriptive statistics and Kaplan-Meier survival estimates. RESULTS: Among 343 patients analyzed, 217 (63.3%) had HR-NMIBC, of whom only 29.5% received adjuvant Bacillus Calmette-Guérin (BCG), often substituted with intravesical gemcitabine because of supply shortages. BCG exposure was associated with superior overall and cancer-specific survival compared with non-BCG patients. In the muscle-invasive cohort (n = 126; 36.7%), cystectomy was performed in 48.4% and significantly improved survival. Perioperative chemotherapy remained limited, with only 39.3% receiving neoadjuvant therapy, and just one third receiving cisplatin-based regimens that conferred the greatest survival benefit. CONCLUSION: This multicenter real-world study exposes major gaps in the management of localized UC in a middle-income setting. Limited access to BCG, perioperative chemotherapy, and cystectomy remain key barriers to guideline-concordant care, underscoring the urgent need for policy actions to improve treatment delivery and outcomes in comparable health care systems.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (4) , e2500324
Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study
PURPOSE: Disparities in health care access and resource availability in middle-income countries often lead to suboptimal management of localized bladder urothelial carcinoma (UC). However, real-world data describing treatment patterns and outcomes in these settings remain limited. METHODS: This multicenter, retrospective, real-world study included patients with high-risk non–muscle-invasive (HR-NMIBC) and localized muscle-invasive bladder cancer (MIBC) diagnosed between 2017 and 2022 across nine cancer centers in a middle-income setting. Treatment data and clinical outcomes were collected from medical records and analyzed using descriptive statistics and Kaplan-Meier survival estimates. RESULTS: Among 343 patients analyzed, 217 (63.3%) had HR-NMIBC, of whom only 29.5% received adjuvant Bacillus Calmette-Guérin (BCG), often substituted with intravesical gemcitabine because of supply shortages. BCG exposure was associated with superior overall and cancer-specific survival compared with non-BCG patients. In the muscle-invasive cohort (n = 126; 36.7%), cystectomy was performed in 48.4% and significantly improved survival. Perioperative chemotherapy remained limited, with only 39.3% receiving neoadjuvant therapy, and just one third receiving cisplatin-based regimens that conferred the greatest survival benefit. CONCLUSION: This multicenter real-world study exposes major gaps in the management of localized UC in a middle-income setting. Limited access to BCG, perioperative chemotherapy, and cystectomy remain key barriers to guideline-concordant care, underscoring the urgent need for policy actions to improve treatment delivery and outcomes in comparable health care systems.
- Open Access
- 1 January 2026
- Published by GN1 Sistemas e Publicacoes Ltd. in Arquivos Brasileiros de Oftalmologia
- Vol. 89 (5) , 1-8
The role of the alpha-gal antigen in corneal xenotransplant rejection: a review
Corneal blindness affects more than 12 million individuals worldwide; however, the availability of human donor corneas meets only a small fraction of the demand. Porcine corneal xenotransplantation represents a promising alternative because of the cornea’s immune privilege and the anatomical similarities between human and porcine corneas. However, the galactose-α1,3-galactose antigen expressed on porcine cells induces hyperacute rejection through the activation of human anti-Gal antibodies, complement pathways, and innate immune cell infiltration. This review summarizes the mechanisms underlying corneal immune privilege and contrasts them with galactose-α1,3-galactose-mediated rejection pathways. In addition, it evaluates five major mitigation strategies: GGTA1-knockout pigs, enzymatic α-galactosidase treatment, RNA interference, decellularization, and immunosuppressive approaches, including CD40-CD154 blockade and topical tacrolimus. Preclinical studies have demonstrated that GTKO corneas can maintain transparency for longer than 1 year, whereas decellularized matrices preserve corneal architecture while exhibiting low antigenicity. These findings support the future clinical translation of porcine corneal xenotransplantation.
- 1 January 2026
- Published by GN1 Sistemas e Publicacoes Ltd. in Arquivos Brasileiros de Oftalmologia
- Vol. 89 (5) , 1-8
Open AccessThe role of the alpha-gal antigen in corneal xenotransplant rejection: a review
Corneal blindness affects more than 12 million individuals worldwide; however, the availability of human donor corneas meets only a small fraction of the demand. Porcine corneal xenotransplantation represents a promising alternative because of the cornea’s immune privilege and the anatomical similarities between human and porcine corneas. However, the galactose-α1,3-galactose antigen expressed on porcine cells induces hyperacute rejection through the activation of human anti-Gal antibodies, complement pathways, and innate immune cell infiltration. This review summarizes the mechanisms underlying corneal immune privilege and contrasts them with galactose-α1,3-galactose-mediated rejection pathways. In addition, it evaluates five major mitigation strategies: GGTA1-knockout pigs, enzymatic α-galactosidase treatment, RNA interference, decellularization, and immunosuppressive approaches, including CD40-CD154 blockade and topical tacrolimus. Preclinical studies have demonstrated that GTKO corneas can maintain transparency for longer than 1 year, whereas decellularized matrices preserve corneal architecture while exhibiting low antigenicity. These findings support the future clinical translation of porcine corneal xenotransplantation.
- Open Access
- 1 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23 ((Suppl 2)) , eEDS1
The role and importance of scientific training in medical school and other healthcare specialties
The issue of scientific training – scientific initiation (SI) in Brazil – for medical students is as old as evidence-based medicine. It goes far beyond training a new generation of physician-scientists needed for the continuous advancement of human health care. Advancements that throughout the 20th century led to doubling the average life expectancy, by saving lives in childhood and prolonging life in adults and the elderly through prophylaxis and treatment of deadly diseases. Science training is crucial for medical students,
- 1 October 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23 ((Suppl 2)) , eEDS1
Open AccessThe role and importance of scientific training in medical school and other healthcare specialties
The issue of scientific training – scientific initiation (SI) in Brazil – for medical students is as old as evidence-based medicine. It goes far beyond training a new generation of physician-scientists needed for the continuous advancement of human health care. Advancements that throughout the 20th century led to doubling the average life expectancy, by saving lives in childhood and prolonging life in adults and the elderly through prophylaxis and treatment of deadly diseases. Science training is crucial for medical students,
- Open Access
- 11 July 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAE1513
Second Edition of the Scientists of Tomorrow/Cientistas do Amanhã Project: advancing scientific thinking, methodology, and equitable education
Highlights ■ Ensuring quality education, providing vocational training, and promoting communication technology, technical, and scientific programs are goals set by the United Nations to enhance learning opportunities for all. ■ Critical thinking, fostered through theoretical and practical activities, is essential for building relevant skills, including literacy and numeracy. ■ The Scientists of Tomorrow/Cientistas do Amanhã project is a reproducible initiative that can be implemented in other research centers and schools. ABSTRACT The Scientists of Tomorrow project is a partnership between
- 11 July 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eAE1513
Open AccessSecond Edition of the Scientists of Tomorrow/Cientistas do Amanhã Project: advancing scientific thinking, methodology, and equitable education
Highlights ■ Ensuring quality education, providing vocational training, and promoting communication technology, technical, and scientific programs are goals set by the United Nations to enhance learning opportunities for all. ■ Critical thinking, fostered through theoretical and practical activities, is essential for building relevant skills, including literacy and numeracy. ■ The Scientists of Tomorrow/Cientistas do Amanhã project is a reproducible initiative that can be implemented in other research centers and schools. ABSTRACT The Scientists of Tomorrow project is a partnership between
- Open Access
Metagenomic Next-Generation Sequencing for the Diagnosis of Infectious Uveitis: A Comprehensive Systematic Review
Background: Infectious uveitis is a potentially sight-threatening condition that requires timely and accurate pathogen identification to guide effective therapy. However, conventional microbiological tests (CMTs) often lack sensitivity and the inclusiveness of pathogen detection. Metagenomic next-generation sequencing (mNGS) offers an unbiased approach to detecting a broad range of pathogens. This review evaluates its diagnostic performance in detecting infectious uveitis. Methods: A systematic search across multiple databases identified studies assessing the use of mNGS for diagnosing infectious uveitis. The included studies compared mNGS to CMTs, including polymerase chain reaction (PCR), culture, serology, and the IGRA (Interferon-Gamma Release Assay). The study characteristics; the detection rates; and the sensitivity, specificity, and predictive values were extracted. The sensitivity and specificity of mNGS were calculated using CMTs as a reference. Results: Twelve studies comprising 859 patients were included. The sensitivity of mNGS compared to that of CMTs ranged from 38.4% to 100%, while specificity varied between 15.8% and 100%. The commonly detected pathogens included varicella-zoster virus, cytomegalovirus, Toxoplasma gondii, and herpes simplex virus. In some cases, mNGS outperformed PCR in viral detection, aiding diagnosis when the standard methods failed. However, contamination risks and inconsistent diagnostic thresholds were noted. Conclusions: mNGS enables the diagnosis of infectious uveitis, particularly for viral causes, but its variable performance and standardization challenges warrant further investigation.
Open AccessMetagenomic Next-Generation Sequencing for the Diagnosis of Infectious Uveitis: A Comprehensive Systematic Review
Background: Infectious uveitis is a potentially sight-threatening condition that requires timely and accurate pathogen identification to guide effective therapy. However, conventional microbiological tests (CMTs) often lack sensitivity and the inclusiveness of pathogen detection. Metagenomic next-generation sequencing (mNGS) offers an unbiased approach to detecting a broad range of pathogens. This review evaluates its diagnostic performance in detecting infectious uveitis. Methods: A systematic search across multiple databases identified studies assessing the use of mNGS for diagnosing infectious uveitis. The included studies compared mNGS to CMTs, including polymerase chain reaction (PCR), culture, serology, and the IGRA (Interferon-Gamma Release Assay). The study characteristics; the detection rates; and the sensitivity, specificity, and predictive values were extracted. The sensitivity and specificity of mNGS were calculated using CMTs as a reference. Results: Twelve studies comprising 859 patients were included. The sensitivity of mNGS compared to that of CMTs ranged from 38.4% to 100%, while specificity varied between 15.8% and 100%. The commonly detected pathogens included varicella-zoster virus, cytomegalovirus, Toxoplasma gondii, and herpes simplex virus. In some cases, mNGS outperformed PCR in viral detection, aiding diagnosis when the standard methods failed. However, contamination risks and inconsistent diagnostic thresholds were noted. Conclusions: mNGS enables the diagnosis of infectious uveitis, particularly for viral causes, but its variable performance and standardization challenges warrant further investigation.
- Open Access
- 13 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAE1133
Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol
Highlights ■ LATAM RegistrAME is the first clinical registry study of spinal muscular atrophy linked to 5q-SMA in Latin America (LATAM), including all ages. ■ This study will provide the first clinical evidence of access to medication for 5q-SMA treatment in LATAM. ■ It will describe the functional assessment and ventilatory support of 5q-SMA patients with diverse sociodemographic aspects. ABSTRACT Spinal muscular atrophy is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. The most common form of
- 13 November 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAE1133
Open AccessLongitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol
Highlights ■ LATAM RegistrAME is the first clinical registry study of spinal muscular atrophy linked to 5q-SMA in Latin America (LATAM), including all ages. ■ This study will provide the first clinical evidence of access to medication for 5q-SMA treatment in LATAM. ■ It will describe the functional assessment and ventilatory support of 5q-SMA patients with diverse sociodemographic aspects. ABSTRACT Spinal muscular atrophy is a rare hereditary neurodegenerative disease characterized by progressive motor neuron loss. The most common form of
- Open Access
- 17 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0821
Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial
Highlights Tofacitinib use did not result in meaningful changes in hematological parameters. Tofacitinib use did not lead to clinically meaningful changes in liver enzymes. ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebotreated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We performed post hoc analyses on the following laboratory tests over time during the
- 17 October 2024
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 22, eAO0821
Open AccessLaboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial
Highlights Tofacitinib use did not result in meaningful changes in hematological parameters. Tofacitinib use did not lead to clinically meaningful changes in liver enzymes. ABSTRACT Objective: Tofacitinib, an oral Janus kinase inhibitor, has been tested against a placebo in 289 patients with COVID-19 pneumonia. We analyzed the data from the tofacitinib- and placebotreated patient cohorts to evaluate the laboratory profiles between baseline and day 7. Methods: We performed post hoc analyses on the following laboratory tests over time during the